RI

RIBOMIC Inc.

Biopharmaceutical firm developing therapeutics using proprietary RNA aptamer technology.

4591 | T

Overview

Corporate Details

ISIN(s):
JP3974850004
LEI:
Country:
Japan
Address:
港区白金台3−16−13 白金台ウスイビル6階

Description

RIBOMIC Inc. is a biopharmaceutical company engaged in the discovery and development of novel molecular-targeted therapeutics using its proprietary RNA aptamer technology. The company's core drug discovery platform, the RiboART System (Ribomic Aptamer Refined Therapeutics System), enables the creation of aptamers that bind to target molecules with high affinity and specificity. RIBOMIC's development pipeline focuses on addressing significant unmet medical needs in various therapeutic areas. Key clinical programs include potential treatments for ophthalmic conditions, such as wet age-related macular degeneration, and rare genetic disorders like achondroplasia.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 08:30
確認書
Japanese 8.0 KB
2025-11-12 08:30
半期報告書-第23期(2025/04/01-2026/03/31)
Japanese 261.6 KB
2025-07-23 08:45
有価証券届出書(組込方式)
Japanese 326.2 KB
2025-06-20 03:50
確認書
Japanese 7.9 KB
2025-06-20 03:49
内部統制報告書-第22期(2024/04/01-2025/03/31)
Japanese 22.3 KB
2025-06-20 03:43
有価証券報告書-第22期(2024/04/01-2025/03/31)
Japanese 2.0 MB
2024-11-13 02:14
確認書
Japanese 7.9 KB
2024-11-13 02:13
半期報告書-第22期(2024/04/01-2025/03/31)
Japanese 207.6 KB
2024-06-26 04:47
臨時報告書
Japanese 22.7 KB
2024-06-26 04:45
内部統制報告書-第21期(2023/04/01-2024/03/31)
Japanese 22.1 KB
2024-06-26 04:44
確認書
Japanese 8.0 KB
2024-06-26 04:43
有価証券報告書-第21期(2023/04/01-2024/03/31)
Japanese 2.0 MB
2024-02-14 02:26
確認書
Japanese 7.9 KB
2024-02-14 02:25
四半期報告書-第21期第3四半期(2023/10/01-2023/12/31)
Japanese 178.6 KB
2023-11-13 08:01
確認書
Japanese 7.9 KB

Automate Your Workflow. Get a real-time feed of all RIBOMIC Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for RIBOMIC Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for RIBOMIC Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.